Red Light Holland announces the first-ever import of psilocybin mushrooms into St. Vincent and the Grenadines.
Red Light Holland announces the first-ever import of psilocybin mushrooms into St. Vincent and the Grenadines.
Awaken receives regulatory approval to begin ketamine-based therapies in its flagship London mental health clinic.
Ketamine Wellness Centers, a subsidiary of Delic Holdings, announces the grand opening of its 13th ketamine clinic.
Novamind announces it will most MindMed's Phase IIb clinical trial of LSD-based therapy for generalized anxiety disorder (GAD).
MINDCURE announces the completion of its strategic review and new cost saving measures.
Enveric Bioscience announces the publishing of four PCT applications by the World Intellectual Property Organization.
Thanks to the advance of psychedelic medicine, "brain injury awareness" is about more than highlighting a problem. It's also about new hope for sufferers.
Numinus announces that its Numinus Bioscience research lab has been approved for a Containment Level 2 (CL2) license from Health Canada.
Bright Minds Biosciences announced the successful completion of a 28-day toxicology study for BMB-101.
Wesana Health reports positive feedback from FDA on pre-IND meeting regarding development of SANA -013 and is anticipating commencing a clinical trial in Q4 2022.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now